Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Robert Fico wins Slovakia election with anti-Ukraine stance
    • Republican hardliner moves to oust Kevin McCarthy over deal to avert shutdown
    • Germans shrug off economic gloom at booming Oktoberfest
    • US lawmakers pass short-term deal to avoid government shutdown
    • Biden seeks to reassure Ukraine as war aid becomes US political battleground
  • UK
    Sections
    • UK Home
    • UK Economy
    • UK Politics
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • UK exporters face hefty EU carbon tax bill after Sunak weakens climate policies
    • BAE Systems wins £3.95bn contract for Aukus nuclear submarines
    • Rishi Sunak will not commit to tax cuts as fractious Tory conference starts
    • New Brexit border checks to cost business £330mn a year
    • UK retailers demand protection from shoplifting surge
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Octopus Energy: the UK start-up outgrowing its roots
    • UBS settles with Mozambique in Credit Suisse ‘tuna bond’ case
    • Revolut attracts UK watchdog scrutiny over red-flag accounts
    • US hedge fund provides record loan for environmental lawsuits
    • Looney accused of promoting BP women with whom he had undisclosed relationships
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • VCs tell start-ups to delay IPO plans after Arm and Instacart underwhelm
    • Revolut attracts UK watchdog scrutiny over red-flag accounts
    • ‘Talk to everyone you can’: Plaid’s Zach Perret on navigating a failed sale and Covid upheaval
    • Afghan currency posts world-beating rally in third quarter
    • The debt-fuelled bet on US Treasuries that’s scaring regulators
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Germany must invest to neutralise the far-right threat
    • Russia and North Korea are baring their teeth
    • Global lessons from inflation’s rise above the UK target
    • Hit the snooze button: it’s good for you
    • Inheritance tax debates overlook the psychology of the thing
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • The ghastly modern office needs a reboot
    • ‘Talk to everyone you can’: Plaid’s Zach Perret on navigating a failed sale and Covid upheaval
    • Success is more complicated than one exceptional individual
    • The activist sued by Elon Musk: ‘We have to show we will not be cowed’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Japan’s toddler superstar: the baby bringing hope to a ghost village
    • Bismarck, Truss and why timing is everything in politics
    • Four unmissable meals – with hotels attached
    • My dad, the demigod
    • Return of the Caesars: the making of emperors and dictators
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Roche Holding AG

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Wednesday, 23 August, 2023
    Drugs research
    Roche inadvertently publishes positive results from lung cancer drug study

    Shares in Swiss pharma group rally after analyst discovers data on immunotherapy medicine on website

    The Roche logo on its headquarters in Basel, Switzerland
  • Tuesday, 22 August, 2023
    Pharmaceuticals sector
    Use of horseshoe crabs’ blue blood puts pharma groups under scrutiny

    BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances

    Person holds a horseshoe crab
  • Monday, 14 November, 2022
    Roche late-stage Alzheimer’s trials end in failure

    Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

    A brain scan showing Alzheimer’s disease
  • Tuesday, 18 October, 2022
    Roche’s sales of Covid drugs fall by $1bn

    Swiss pharma group says demand for coronavirus tests dropped as severity of virus ebbed

    Roche chief executive Severin Schwan
  • Thursday, 21 July, 2022
    Roche’s chief executive to step down and become chair

    Severin Schwan will be succeeded by Thomas Schinecker, head of drugmaker’s diagnostics unit

    Severin Schwan has helmed Roche as chief executive since 2008
  • Monday, 25 April, 2022
    LexCoronavirus treatment
    Roche/diagnostics: Covid vaccine victory means test makers take a rest Premium content

    Do not dismiss the possibility of another upturn in the coronavirus testing market

    A man gets tested for Covid in New York City
  • Monday, 25 April, 2022
    Roche sales boosted by North American demand for Covid tests

    Swiss pharmaceuticals group expects revenue from coronavirus treatments will decline this year

    A Roche rapid test for coronavirus
  • Wednesday, 6 April, 2022
    LexPharmaceuticals sector
    Breast cancer: precision drugs make inroads against stubborn tumours Premium content

    New therapies replace a blunderbuss with a stiletto

    A phial and packs of Herceptin sit on a pharmacy shelf
  • Thursday, 4 November, 2021
    Novartis to sell its Roche stake worth $21bn

    Twenty-year shareholding had kept the two Swiss drugmakers closely linked

    Roche logo
  • Thursday, 5 August, 2021
    Due Diligence
    SoftBank’s newfangled bet on a 125-year-old drugmaker Premium content

    Plus, inside the cut-throat game of private equity and European football

  • Wednesday, 4 August, 2021
    LexPharmaceuticals sector
    SoftBank/Roche: Northstar reorients to embrace drug development Premium content

    The Swiss company and Japanese tech investor both have a taste for big data and disruption

    Roche HQ in Basel, Switzerland
  • Wednesday, 4 August, 2021
    SoftBank Group Corp
    SoftBank acquires $5bn stake in Swiss drugmaker Roche

    Deal struck through unit of Japanese technology group that was behind ‘Nasdaq whale’ trade

    A Roche plant in the Swiss village of Rotkreuz
  • Monday, 5 July, 2021
    News in-depthPharmaceuticals sector
    Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

    Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

  • Thursday, 13 May, 2021
    Covid-19 vaccines
    Roche chief compares waiving vaccine patents to East German nationalisation

    Severin Schwan believes proposal is ‘counterproductive’ and will not solve supply shortages

    Severin Schwan
  • Wednesday, 21 April, 2021
    Covid-19 test demand boosts Roche

    Swiss pharmaceutical company reports 55% jump in diagnostic sales

    A Roche Covid-19 self-test
  • Friday, 2 April, 2021
    LexPharmaceuticals sector
    Roche/Novartis: rivals play king of the pill Premium content

    The pharmaceuticals are battling in similar markets, but their share price performances have diverged

  • Thursday, 15 October, 2020
    Roche says broader tests needed for second Covid wave

    ‘If you look at the curves going up everywhere, relying on PCR alone will not work’

  • Tuesday, 6 October, 2020
    Coronavirus treatment
    NHS labs hit by shortage of vital kit and chemicals for Covid tests

    Supplier Roche warns of disruption as infections rise sharply

  • Wednesday, 22 July, 2020
    ExplainerCoronavirus
    Test, test, test — but what can America do about the delays?

    Patients in the US are waiting more than a week for results, by which time it’s probably too late

  • Wednesday, 24 June, 2020
    Due Diligence
    Banks: back to the office Premium content

    The question is how a return to work can be made safe without a vaccine?

  • Tuesday, 23 June, 2020
    Inside BusinessKana Inagaki
    A Swiss-Japanese alliance that has thrived in the crisis

    Roche and Chugai provide lessons on how to keep a cross-border partnership intact

    Nearly two decades after Roche bought a controlling stake in Chugai, the alliance has not only survived but has prospered during the coronavirus crisis
  • Tuesday, 16 June, 2020
    Coronavirus
    UK antibody test access stokes frustration and confusion

    Consumers and doctors eager to understand who has immunity face uncertainty over testing and reliability

  • Thursday, 21 May, 2020
    Coronavirus
    Free NHS antibody tests on way after Roche and Abbott Labs deals

    And trials of 20-minute swab test to determine coronavirus infection will start next week

  • Friday, 15 May, 2020
    Coronavirus
    Abbott joins Roche in winning UK approval for virus antibody test

    Public Health England gives green light to second diagnostic kit to detect past infection and potential immunity

  • Wednesday, 13 May, 2020
    Public Health England
    Public Health England gives green light to coronavirus antibody test

    Approval for Roche project paves way for checks on who has had disease and who has potential immunity

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Economy
    • UK Politics
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today’s Newspaper (FT Digital Edition)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In